Literature DB >> 34023044

Diabetes and Osteoporosis: Part II, Clinical Management.

G Isanne Schacter1, William D Leslie2.   

Abstract

Diabetes-induced osteoporosis is characterized by an increase in fracture risk. FRAX, the most widely used tool, underestimates the risk of fracture in both type 1 and type 2 diabetes. Specific adjustments to FRAX can help to better identify patients with diabetes at increased risk of fracture and select those at high fracture risk for treatment. Although clinical trial data are limited, the available evidence indicates that the presence of diabetes does not alter antiosteoporotic treatment response in patients with diabetes.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone; Bone mineral density; Diabetes; Dual-energy x-ray absorptiometry; Fracture; Osteoporosis

Mesh：

Year:  2021        PMID： 34023044     DOI： 10.1016/j.ecl.2021.03.006

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN： 0889-8529            Impact factor:   4.741


  2 in total

1.  Upregulated miR-9-5p inhibits osteogenic differentiation of bone marrow mesenchymal stem cells under high glucose treatment.

Authors:  Chuanmei He; Mingming Liu; Qun Ding; Fumeng Yang; Tongdao Xu
Journal:  J Bone Miner Metab       Date:  2021-11-09       Impact factor: 2.626

Review 2.  Update of the fracture risk prediction tool FRAX: a systematic review of potential cohorts and analysis plan.

Authors:  L Vandenput; H Johansson; E V McCloskey; E Liu; K E Åkesson; F A Anderson; R Azagra; C L Bager; C Beaudart; H A Bischoff-Ferrari; E Biver; O Bruyère; J A Cauley; J R Center; R Chapurlat; C Christiansen; C Cooper; C J Crandall; S R Cummings; J A P da Silva; B Dawson-Hughes; A Diez-Perez; A B Dufour; J A Eisman; P J M Elders; S Ferrari; Y Fujita; S Fujiwara; C-C Glüer; I Goldshtein; D Goltzman; V Gudnason; J Hall; D Hans; M Hoff; R J Hollick; M Huisman; M Iki; S Ish-Shalom; G Jones; M K Karlsson; S Khosla; D P Kiel; W-P Koh; F Koromani; M A Kotowicz; H Kröger; T Kwok; O Lamy; A Langhammer; B Larijani; K Lippuner; D Mellström; T Merlijn; A Nordström; P Nordström; T W O'Neill; B Obermayer-Pietsch; C Ohlsson; E S Orwoll; J A Pasco; F Rivadeneira; B Schei; A-M Schott; E J Shiroma; K Siggeirsdottir; E M Simonsick; E Sornay-Rendu; R Sund; K M A Swart; P Szulc; J Tamaki; D J Torgerson; N M van Schoor; T P van Staa; J Vila; N J Wareham; N C Wright; N Yoshimura; M C Zillikens; M Zwart; N C Harvey; M Lorentzon; W D Leslie; J A Kanis
Journal:  Osteoporos Int       Date:  2022-05-31       Impact factor: 5.071
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.